Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study)
In-Kyung Jeong, Sung-Rae Kim, In-Kyung Jeong, Sung-Rae Kim
Abstract
Background: While randomized controlled trials provide useful information about drug safety and efficacy, they do not always reflect the observed results in the real world. The prospective, observational, non-comparative trial in South Korea was designed to evaluate the efficacy and safety of pitavastatin in clinical practice in 28,343 patients.
Methods: This study was conducted in 893 facilities in Korea from April 2, 2012 to April 1, 2017. This study was designed to administer 1, 2, or 4 mg pitavastatin to patients with hyperlipidemia at the age of 20 or older for at least 8 weeks.
Results: For 126 days of mean duration of administration of pitavastatin, the % change of low density lipoprotein cholesterol indicated a dose dependent reduction: -23.4%, -29.1%, and -35.2% in the 1, 2, and 4 mg groups, respectively in patients who have not been treated with lipid lowering medications prior to study. Only 1.74% (492/28,343) of pitavastatin-treated patients experienced adverse events, of which 0.43% (123/28,343) were adverse drug reactions. Less than 1% of patients experienced the grade 2 or more toxicity (Common Terminology Criteria for Adverse Events v4.03) in alanine aminotransferase, aspartate aminotransferase, serum creatinine, and serum creatine phosphokinase. Although there were no rhabdomyolysis in 28,343 patients, 0.04% of patients had been reported pitavastatin-related musculoskeletal disorders.
Conclusion: Overall, this observational study showed that pitavastatin was well tolerated and effectively modified the lipid profile, reducing cardiovascular and cerebrovascular risk in Korean patients with hypercholesterolemia in the real world.
Keywords: Cholesterol, LDL; Observational study; Pitavastatin; Rhabdomyolysis; Safety.
Conflict of interest statement
CONFLICTS OF INTEREST
This study was funded by the JW Pharmaceutical Corporation.
Figures
References
- World Health Organization. Cardiovascular diseases (CVDs) [Internet] Geneva: WHO; 2017. [cited 17 May 2017]. Available from:
- Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med. 2019;34:723–71.
- Saito Y, Teramoto T, Yamada N, Itakura H, Hata Y, Nakaya N, et al. Clinical efficacy of NK-104 (pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the dose finding, double blind, three-group comparative study. J Clin Therap Med. 2001;17:829–55.
- Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–61.
- Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25:2755–64.
- Kwon JE, Kim Y, Hyun S, Won H, Shin SY, Lee KJ, et al. Cholesterol lowering effects of low-dose statins in Korean patients. J Lipid Atheroscler. 2014;3:21–8.
- Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007;29:2365–73.
- Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation. 2018;137:1997–2009.
- Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:e38–81.
- De Alava E, Sola JJ, Lozano MD, Pardo-Mindan FJ. Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants. Nephron. 1994;66:242–3.
- Fernandez Zatarain G, Navarro V, Garcia H, Villatoro J, Calvo C. Rhabdomyolysis and acute renal failure associated with lovastatin. Nephron. 1994;66:483–4.
- Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000;23:197–213.
- Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C, Scottolini AG. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem. 1990;36:2145–7.
- Pfizer Limited. Atorvastatin 10 mg Film Coated Tablets: Summary of Product Characteristics (SmPC) [Internet] The electronic medicines compendium (emc) 2019 [cited 2020 Oct 29]. Available from: .
- Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler Suppl. 2011;12:285–8.
- Betteridge J. Pitavastatin: results from phase III & IV. Atheroscler Suppl. 2010;11:8–14.
- Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther. 2011;9:555–62.
- National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v403. Bethesda: U.S. Department of Health and Human Services, National Institutes of Health; 2010.
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.
- Cohen DE, Anania FA, Chalasani N National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8A):77C–81C.
- Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.
- Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97(8A):32C–43C.
- Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018;15:757–69.
- Sylvain-Moore H, Worden JP., Jr Lovastatin-associated rhabdomyolysis. Heart Lung. 1991;20(5 Pt 1):464–6.
- Waclawik AJ, Lindal S, Engel AG. Experimental lovastatin myopathy. J Neuropathol Exp Neurol. 1993;52:542–9.
- Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother. 1992;26:190–2.
- Hume AL. Comment: lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother. 1992;26:1303.
- Pedro-Botet J, Nunez-Cortes JM, Flores JA, Rius J. Muscle symptoms related with statin therapy in general practice. Atherosclerosis. 2015;241:e197.
- Khan A, Maki KC, Ito MK, Cohen JD, Sponseller CA, Bell M, et al. Statin associated muscle symptoms: characteristics of patients and recommendations by providers. J Clin Lipidol. 2015;9:460.
- Crouse JR, Grundy SM. Effects of alcohol on plasma lipoproteins and cholesterol and triglyceride metabolism in man. J Lipid Res. 1984;25:486–96.
- Wakabayashi I. Alcohol intake and triglycerides/high-density lipoprotein cholesterol ratio in men with hypertension. Am J Hypertens. 2013;26:888–95.
- Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
- Betteridge DJ, Carmena R. The diabetogenic action of statins: mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12:99–110.
- Choi SH, Lim S, Hong ES, Seo JA, Park CY, Noh JH, et al. PROPIT: a PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. Clin Endocrinol (Oxf) 2015;82:670–7.
- Jeong HS, Hong SJ, Son S, An H, Kook H, Joo HJ, et al. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Cardiovasc Diabetol. 2019;18:162.
- Choi JY, Choi CU, Hwang SY, Choi BG, Jang WY, Kim DY, et al. Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction. Am J Cardiol. 2018;122:922–8.
Source: PubMed